Oral bacterial vaccines for the prevention of acute exacerbations in chronic obstructive pulmonary disease and chronic bronchitis.
Oral vaccines using killed bacterial extracts have been used to prevent acute exacerbations of chronic obstructive pulmonary disease (COPD); however, they are not recommended by current clinical guidelines. Two systematic reviews have been published on the efficacy of oral vaccines. The first, on the effects of an oral whole-cell nontypeable Haemophilus influenzae vaccine (NTHi) found a significant decrease in the incidence of acute episodes of chronic bronchitis (Poisson rate ratio 0.666; 95% confidence interval (CI) 0.500, 0.887; P = 0.005), and a 58% reduction in the prescription of antibiotics 3 months after vaccination. The second review evaluated studies that used multicomponent vaccines. It found that the duration of exacerbations was significantly shorter in the treatment group (weighted mean difference -2.7 days, 95% CI -3.5 to -1.8). These reviews suggest that oral vaccines reduce the number, severity, duration, or both, of acute exacerbations. However, many of the primary trials on which they are based are small and methodologically flawed. Further trials are needed before the use of oral vaccines could be considered as part of the routine clinical management of patients with COPD or chronic bronchitis.
Arandjus
Claire
C
Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand. carandjus@auckland.ac.nz
Black
Peter N
PN
Poole
Phillippa J
PJ
Wood Baker
Richard
R
Steurer-Stey
Claudia
C
D000284:Administration, Oral; D001428:Bacterial Vaccines / Q000008:administration & dosage*; D001991:Bronchitis / Q000517:prevention & control*; D002908:Chronic Disease; D006801:Humans; D029424:Pulmonary Disease, Chronic Obstructive / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic
D001428:Bacterial Vaccines